

06 May 2021 | News

QUOTED. 6 May 2020. Paul Diaz.

by

Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.

"We are now focused on three business units, where we can be a market leader. We've made hard decisions across the organization to right-size our cost structure." – Paul Diaz, CEO, Myriad

• Find out more: *Labcorp Buys Myriad Genetics' Vectra Autoimmune Test Business*

<u>Click here</u> for a free trial of Medtech Insight